Comparative Efficacy of Trovafloxacin in Experimental Endocarditis Caused by Ciprofloxacin-Sensitive, Methicillin-Resistant Staphylococcus aureus | Zendy

Young S. Kim | Zendy; Quingxiang Liu | Zendy; Lucien L. Chow | Zendy; Henry F. Chambers | Zendy; Martin G. Täuber | Zendy

Open Access

Comparative Efficacy of Trovafloxacin in Experimental Endocarditis Caused by Ciprofloxacin-Sensitive, Methicillin-Resistant Staphylococcus aureus

Author(s) -

Young S. Kim,

Quingxiang Liu,

Lucien L. Chow,

Henry F. Chambers,

Martin G. Täuber

Publication year - 1998

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.42.12.3325

Subject(s) - trovafloxacin , ciprofloxacin , sulbactam , microbiology and biotechnology , medicine , staphylococcus aureus , vancomycin , endocarditis , ampicillin , methicillin resistant staphylococcus aureus , antibacterial agent , antibiotics , biology , imipenem , bacteria , antibiotic resistance , genetics

The new fluoroquinolone trovafloxacin was tested against a ciprofloxacin-sensitive, methicillin-resistantStaphylococcus aureus strain in the rabbit model of endocarditis. Trovafloxacin was more effective than vancomycin (CFU/g of vegetation, 2.65 ± 1.87 versus 4.54 ± 2.80 [mean ± standard deviation]; P < 0.05) or ampicillin-sulbactam plus rifampin (4.9 ± 1.1 CFU/g). The addition of ampicillin-sulbactam to trovafloxacin tended to reduce titers further.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research